Telesis Bio Q1 revenue $3.4M down 46% YoY; net loss $8.6M improves from $11.1M

Telesis Bio Inc.

2024-Q1 EPS reported -$5.52 revenue$3,440,000

Revenue $3.4M vs $6.3M YoY; product revenue fell $1.7M and collaboration revenue $1.0M.
Net loss $8.6M ($5.52 EPS) vs $11.1M ($6.75 EPS) YoY; operating expenses cut 31% to $10.0M.
Cash, equivalents and investments $15.7M at March 31, 2024; long-term notes payable $5.2M.
Strategic focus on Gibson SOLA and BioXp mRNA; 40% of new instrument buyers cite mRNA workflow.
Pfizer collaboration progressing; no forward-looking guidance provided.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Telesis Bio Inc. reported the quarter ended March 31, 2024 results: revenue $3.4 million, net income $8.6 million, EPS $5.52.

Period: the quarter ended March 31, 2024
Revenue: $3.4 million
Net income: $8.6 million
EPS: $5.52
Result: reported results

Exact text from the filing

strategy, is reduced 31% from the first quarter of the prior year. Summary of First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 was $3.4 million compared to $6.3 million for the three months ended March 31, 2023. The decrease of $2.9 million was attributable to a decrease in product revenue of $1.7 million, a decrease in

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.